ethosuximide and Child Behavior Disorders

ethosuximide has been researched along with Child Behavior Disorders in 6 studies

Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.

Child Behavior Disorders: Disturbances considered to be pathological based on age and stage appropriateness, e.g., conduct disturbances and anaclitic depression. This concept does not include psychoneuroses, psychoses, or personality disorders with fixed patterns.

Research

Studies (6)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Number of Participants With Attention Deficit as Measured by the Confidence Index of the CPT-II and the K-CPT

A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy

Number of Participants With Freedom From Treatment Failure at 12 Months of Double Blind Therapy

Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 12 months of double blind therapy

Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy

Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy

Trials

2 trials available for ethosuximide and Child Behavior Disorders

Other Studies

4 other studies available for ethosuximide and Child Behavior Disorders